Stock listing

NASDAQ:TYRA Tyra Biosciences, Inc. Stock

Home listing (NASDAQ) of Tyra Biosciences, Inc.

Follow Tyra Biosciences, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:TYRA

$20.12 USD +0.51 (+2.6%)

Close on Nov 20, 2026

Past year -4.2% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$19.48 – $20.44 USDNov 20, 2026
Volume
467,578 sharesNov 20, 2026
Market cap
$1.39B USDAt the close on Nov 20, 2026 · price × 69.08M shares outstanding
52-week range
$18.25 – $40.65 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$19.11M USDMedian day 648,973 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Tyra Biosciences, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:TYRA · Home$20.12 USD+0.51 (+2.6%)467,578$19.62$20.44$19.48$19.61Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:TYRA · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$20.12+0.51+2.6%$19.62$20.44$19.48467,578
$19.61+0.04+0.2%$19.50$20.27$19.26472,171
$19.57-0.17-0.9%$20.17$20.79$19.34690,592
$19.74-0.285-1.4%$20.03$20.61$19.60803,180
$20.03+0.26+1.3%$19.99$20.12$19.27375,083
$19.77-1.205-5.7%$20.67$21.43$19.66857,073
$20.97-0.03-0.1%$20.98$21.39$20.72532,706
$21.00-1.30-5.8%$22.00$22.58$20.80793,825
$22.30+1.15+5.4%$21.35$23.00$20.89343,151
$21.15+0.26+1.2%$21.22$21.59$20.75862,264
$20.89-0.635-3.0%$21.54$21.65$20.79694,655
$21.53+0.155+0.7%$21.91$21.91$20.78542,625
$21.37+0.04+0.2%$21.50$21.94$21.23433,755
$21.33+0.26+1.2%$21.08$21.62$20.75539,379
$21.07-0.41-1.9%$21.18$21.55$20.32625,768
$21.48-0.27-1.2%$21.92$22.37$21.10734,901
$21.75+0.23+1.1%$21.31$21.79$21.16354,870
$21.52+1.10+5.4%$20.45$21.59$20.05523,033
$20.42-0.03-0.1%$20.76$21.00$20.31790,339
$20.45-0.42-2.0%$20.85$20.85$20.09520,381
$20.87+0.27+1.3%$20.58$21.28$20.22826,147
$20.60+0.13+0.6%$20.52$20.99$20.13724,341
$20.47+1.13+5.8%$19.42$20.58$19.35607,591
$19.34+0.82+4.4%$18.75$19.49$18.49871,846
$18.52-0.52-2.7%$19.09$19.09$18.26648,973
$19.04+0.34+1.8%$18.86$19.30$18.76418,028
$18.70+0.14+0.8%$18.44$18.83$18.25483,997
$18.56-1.04-5.3%$19.39$19.60$18.54469,540
$19.60-0.34-1.7%$19.73$20.03$19.51334,413
$19.94-0.03-0.2%$19.93$20.59$19.73649,439
$19.97-0.42-2.1%$20.12$20.17$19.50792,255
$20.39+0.15+0.7%$19.97$20.79$19.80477,743
$20.24-0.69-3.3%$20.93$20.99$19.60763,383
$20.93+0.50+2.4%$20.57$21.03$19.94614,360
$20.43-0.58-2.8%$21.25$21.39$20.171,047,667
$21.01-0.86-3.9%$21.78$22.32$20.88889,699
$21.87-0.11-0.5%$22.19$22.45$21.701,034,684
$21.98+0.53+2.5%$21.37$22.62$21.29501,797
$21.45-0.31-1.4%$21.57$21.93$21.00824,582
$21.76-0.65-2.9%$22.33$22.41$21.671,421,983
$22.41-0.82-3.5%$23.17$23.41$22.121,090,085
$23.23-2.34-9.2%$25.27$25.39$22.861,102,779
$25.57-0.08-0.3%$25.77$26.43$25.201,215,889
$25.65-0.08-0.3%$26.04$26.96$25.40989,217
$25.73+1.30+5.3%$24.58$25.88$24.402,069,688
$24.43+0.08+0.3%$24.80$25.17$24.27511,825
$24.35-1.08-4.2%$25.58$26.15$24.151,138,620
$25.43+0.36+1.4%$24.71$25.78$24.151,142,331
$25.07+3.04+13.8%$23.20$26.36$23.202,066,103
$22.03-1.51-6.4%$23.63$23.96$21.861,548,636
$23.54+1.53+7.0%$21.41$23.64$21.272,477,607
$22.01-4.72-17.7%$18.94$22.30$18.666,069,061
$26.73-1.92-6.7%$27.95$29.49$26.701,158,785
$28.65+3.79+15.2%$24.51$29.56$24.511,864,601
$24.86-0.27-1.1%$25.22$25.59$24.61603,551
$25.13-0.17-0.7%$25.52$26.42$24.80567,917
$25.30+0.27+1.1%$24.99$25.59$24.84423,512
$25.03+0.09+0.4%$24.82$25.21$24.17423,798
$24.94-1.19-4.6%$25.88$25.88$24.91217,500
$26.13-0.09-0.3%$26.17$26.69$25.92253,994
$26.22-0.47-1.8%$26.63$26.79$26.03286,933
$26.69+0.60+2.3%$26.47$26.99$26.30317,813
$26.09+0.04+0.2%$25.99$26.42$25.18321,120
$26.05+0.36+1.4%$25.95$26.81$25.95493,596
$25.69-1.12-4.2%$26.36$26.36$25.08324,478
Ticker
NASDAQ:TYRA
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Tyra Biosciences, Inc. news

Tyra Biosciences, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
13 in the last 12 months · 67 in all · newest Nov 10, 2026 · oldest 2021
Decks
3 decks · latest September 2026

Where Tyra Biosciences, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:TYRA · Home listing · This pageNASDAQUnited StatesUSD
BOATS:TYRABOATSUnited StatesUSD

Valuation

Price/book 2.0× against a median of 2.9×: 3rd lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$694.9M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
2.0×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
0.40

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Tyra Biosciences, Inc. · NASDAQ:TYRAUS$1.39BUS$694.9Mn/an/an/a2.0×n/a0.0×0.40
Sarepta Therapeutics, Inc. · NASDAQ:SRPTUS$1.43BUS$1.41Bn/a0.7×n/a0.9×−5.9%0.6×1.70
ADARx Pharmaceuticals, Inc. · NASDAQ:ADRXUS$1.42BUS$521.8Mn/a77.6×n/a2.5×n/a0.0×n/a
Nurix Therapeutics, Inc. · NASDAQ:NRIXUS$1.40BUS$683.6M4.8×1.0×n/a1.4×42.0%0.0×1.15
Intellia Therapeutics, Inc. · NASDAQ:NTLAUS$1.40BUS$1.00Bn/a19.0×n/a2.3×−805.7%0.1×2.01
Wuhan Healthgen Biotechnology Corp Class A · SSE:688765US$1.37BUS$1.37Bn/a164×n/a3.3×−252.8%0.1×n/a
Rapport Therapeutics, Inc. · NASDAQ:RAPPUS$1.37BUS$987.3Mn/a49.4×n/a3.5×−752.4%0.0×1.16
Immunocore Holdings plc · NASDAQ:IMCRUS$1.36BUS$463.6Mn/a1.1×n/a3.3×−7.5%0.0×0.62
Nanobiotix SA · EURONEXT:NANOUS$1.36BUS$1.36Bn/a41.7×n/an/a−80.8%n/an/a
uniQure N.V. · NASDAQ:QUREUS$1.36BUS$739.1Mn/a36.6×n/a4.6×n/a0.2×1.25
UroGen Pharma Ltd. · NASDAQ:URGNUS$1.36BUS$1.46Bn/a5.8×n/an/a−26.3%n/a1.23
Median of the othersUS$1.37BUS$995.2M4.8×27.8×2.9×−53.5%0.1×1.23

Forecasts

12 strong buy · 2 buy · 1 hold · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.

Price target
47.45 USD · Analysts' mean
EPS, year to Dec 2026
-2.69 · 13 analysts

Team and board

Officers

OfficerRole
Todd HarrisChief Executive Officer
Alan FuhrmanChief Financial Officer
Bhavesh AsharChief Operating Officer
Ali FawazGeneral Counsel and Secretary
Jonathan DayEVP, Clinical Development
Sarah HonigSVP, Corporate Development & Strategy
Daniel BensenChief Discovery Officer
Doug WarnerChief Medical Officer
Heather FauldsChief Regulatory Officer
Liz PaganoChief Human Resources Officer
Piyush PatelChief Development Officer
Robert L. HudkinsChief Technology Officer
Ronald V. SwansonChief Scientific Officer

Board

DirectorRole
Adele GulfoBoard Member
Habib DableBoard Member
Jake SimsonBoard Member
Melissa McCrackenBoard Member
Rehan VerjeeBoard Member
Robert MoreBoard Member
S. Michael RothenbergBoard Member
Susan MoranBoard member

Events

QuarterResultsShare move
Q3 2026Nov 10, 2026 · Before open−5.8%
Q2 2026Aug 4, 2026 · After close−21.0%
Q1 2026Apr 30, 2026+0.8%
Q4 2025Mar 2, 2026 · After close+1.5%
Q3 2025Nov 5, 2025 · After close−3.6%
Q2 2025Aug 14, 2025 · After close+0.3%
Q1 2025May 8, 2025 · After close+0.2%
Q4 2024Mar 27, 2025−4.6%
Q3 2024Nov 7, 2024 · After close−6.1%
Q2 2024Aug 7, 2024 · After close+4.3%
All 20 quarters
QuarterResultsShare move
Q1 2024May 9, 2024 · After close−2.3%
Q4 2023Mar 19, 2024 · After close+7.9%
Q3 2023Nov 7, 2023 · After close−1.3%
Q2 2023Aug 10, 2023 · After close+1.9%
Q1 2023May 4, 2023 · After close−2.8%
Q4 2022Mar 22, 2023 · After close+1.9%
Q3 2022Nov 3, 2022 · After close−0.1%
Q2 2022Aug 4, 2022 · After close+15.0%
Q1 2022May 5, 2022 · After close+4.9%
Q4 2021Mar 3, 2022 · After close−1.5%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (September 2026)Investor deck47 slidesSeptember 2026
Corporate Update (October 2024)Corporate update38 slidesOct 25, 2024
ENA Symposium (Abstract 500 LBA)Conference23 slides

Open Decks

Financings

RaiseDate
Public offering of common stock and pre-funded warrants
Announced: about US$400M · US$22.03 a share · Jefferies +7
Dealers: Jefferies (co-lead), Guggenheim Securities (co-lead), Cantor (co-lead), Barclays (co-lead), William Blair (co-lead), Wedbush PacGrow, Raymond James, Oppenheimer & Co.
Buyers: RA Capital Management (led the offering); Invus; Commodore Capital; BVF Partners; Janus Henderson Investors; Trails Edge Capital Partners; Integral Health Asset Management; TCGX; StemPoint Capital LP
Use of proceeds: Advance dabogratinib development in LG-UTUC, IR NMIBC and achondroplasia, preclinical and discovery programs, working capital and general corporate purposes
Sep 14, 2026

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$16.00 a share on Sep 14, 2021.

Price
US$16.00 a share
Shares offered
10,800,000 shares of common stock
Offering size
US$172.8 million
Underwriters' option
Up to 1,620,000 more shares
Underwriters
BofA Securities, Jefferies, Cowen · In the order on the cover
Shares delivered
On or about Sep 17, 2021

Steps

StepWhen
Draft sent to the SEC in confidenceMay 28, 2021
Filed publiclyAug 20, 2021
Amended twiceNewest Sep 14, 2021
Shares registered with an exchangeSep 10, 2021
Declared effective by the SECSep 14, 2021
Final prospectus, with the priceSep 15, 2021

Open IPO · From the cover of the final prospectus (424B4) filed Sep 15, 2021

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue0000000
Cost of revenue546.0K519.0K353.0K296.0K140.0K47.0K8.00K
Gross profit-546.0K-519.0K-353.0K-296.0K-140.0K-47.0K-8.00K
Research and development102.9M80.1M62.5M43.0M20.6M7.20M1.79M
Selling, general and administrative29.8M24.1M17.4M15.9M5.65M2.09M1.33M
Operating income-132.8M-104.2M-79.9M-58.9M-26.3M-9.30M-3.12M
Depreciation and amortization546.0K519.0K357.0K296.0K140.0K47.0K8.00K
EBITDA-132.2M-103.7M-79.6M-58.6M-26.1M-9.25M-3.11M
Interest expense296.0K140.0K1.00K1.00K
Income before tax-119.9M-86.5M-69.1M-55.3M-26.3M-9.34M-4.07M
Income tax0002.00K1.00K1.00K-7.00K
Net income-119.9M-86.5M-69.1M-55.3M-26.3M-9.34M-4.06M
Earnings per share, basic-2.01-1.51-1.62-1.32-1.91-6.05-0.10
Earnings per share, diluted-2.01-1.51-1.62-1.32-1.91-6.05

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash and equivalents77.4M92.0M58.0M251.2M302.2M15.2M108.0K
Short-term investments178.6M249.5M145.5M0
Receivables2.00M700.0K
Current assets265.4M347.5M211.7M257.3M304.1M15.3M127.0K
Property, plant and equipment1.31M1.65M1.63M1.08M1.03M297.0K276.0K
Total assets282.6M363.6M225.9M266.2M306.7M16.0M528.0K
Accounts payable1.18M590.0K4.66M1.15M599.0K664.0K327.0K
Current liabilities18.1M14.6M15.3M5.70M3.62M1.86M5.16M
Total debt5.81M6.22M6.50M2.62M1.18M142.0K253.0K
Total liabilities23.4M20.4M21.6M8.35M4.96M2.00M5.27M
Shareholders' equity259.2M343.2M204.3M257.8M301.7M-13.6M-4.74M
Shares outstanding53.7M50.7M43.0M42.4M41.4M1.83M42.5M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash from operations-95.1M-69.8M-50.1M-50.3M-23.7M-7.76M-2.62M
Capital spending-141.0K-664.0K-770.0K-559.0K-661.0K-312.0K-20.0K
Free cash flow-95.3M-70.4M-50.9M-50.8M-24.4M-8.07M-2.64M
Cash from investing72.5M-98.4M-144.6M-559.0K-645.0K-312.0K-20.0K
Cash from financing8.10M202.1M1.54M632.0K311.3M23.4M157.0K
Share buybacks0-420.0K0311.4M
Change in cash-14.6M34.0M-193.2M-50.2M287.0M15.4M-2.48M

Open Financials

Filings

FilingDateTypeFiled with
10-Q · Quarterly reportNov 10, 2026Quarterly reportSEC
8-K · Current reportNov 10, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedOct 27, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeSep 21, 2026Big-stake noticeSEC
4 · Change in ownershipSep 17, 2026Insider tradeSEC
4 · Change in ownershipSep 17, 2026Insider tradeSEC
4 · Change in ownershipSep 17, 2026Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedSep 17, 2026Big-stake noticeSEC
4 · Change in ownershipSep 17, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeSep 17, 2026Big-stake noticeSEC
Show 200 filings
FilingDateTypeFiled with
8-K · Current reportSep 14, 2026Current reportSEC
424B5 · ProspectusSep 14, 2026Offer documentSEC
FWP · Free writing prospectusSep 14, 2026Offer documentSEC
S-3ASR · Registration statementSep 14, 2026Offer documentSEC
4 · Change in ownershipSep 11, 2026Insider tradeSEC
8-K · Current reportSep 9, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
424B5 · ProspectusAug 4, 2026Offer documentSEC
10-Q · Quarterly reportAug 4, 2026Quarterly reportSEC
8-K · Current reportAug 4, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeJul 30, 2026Big-stake noticeSEC
144 · Notice of proposed saleJun 26, 2026Other filingsSEC
8-K · Current reportJun 2, 2026Meeting outcomeSEC
4 · Change in ownershipJun 1, 2026Insider tradeSEC
4 · Change in ownershipJun 1, 2026Insider tradeSEC
4 · Change in ownershipJun 1, 2026Insider tradeSEC
4 · Change in ownershipJun 1, 2026Insider tradeSEC
4 · Change in ownershipJun 1, 2026Insider tradeSEC
4 · Change in ownershipJun 1, 2026Insider tradeSEC
4 · Change in ownershipJun 1, 2026Insider tradeSEC
144 · Notice of proposed saleJun 1, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 14, 2026Big-stake noticeSEC
10-Q · Quarterly reportMay 13, 2026Quarterly reportSEC
8-K · Current reportMay 13, 2026ResultsSEC
144 · Notice of proposed saleMay 12, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 12, 2026Big-stake noticeSEC
4 · Change in ownershipMay 7, 2026Insider tradeSEC
4 · Change in ownershipMay 7, 2026Insider tradeSEC
4 · Change in ownershipMay 7, 2026Insider tradeSEC
4 · Change in ownershipMay 7, 2026Insider tradeSEC
4 · Change in ownershipMay 7, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedApr 24, 2026Big-stake noticeSEC
4 · Change in ownershipApr 20, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 20, 2026Insider tradeSEC
ARS · Annual report to shareholdersApr 17, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 17, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 17, 2026Meeting noticeSEC
8-K · Current reportApr 17, 2026Management or board changeSEC
144 · Notice of proposed saleApr 13, 2026Other filingsSEC
SCHEDULE 13G · Big-stake noticeApr 7, 2026Big-stake noticeSEC
3 · Initial statement of ownershipApr 2, 2026Insider tradeSEC
8-K · Current reportApr 2, 2026Management or board changeSEC
4 · Change in ownershipMar 27, 2026Insider tradeSEC
144 · Notice of proposed saleMar 26, 2026Other filingsSEC
144 · Notice of proposed saleMar 25, 2026Other filingsSEC
4 · Change in ownershipMar 17, 2026Insider tradeSEC
4 · Change in ownershipMar 17, 2026Insider tradeSEC
144 · Notice of proposed saleMar 12, 2026Other filingsSEC
SCHEDULE 13D/A · Big-stake notice, amendedMar 6, 2026Big-stake noticeSEC
8-K · Current reportMar 4, 2026Current reportSEC
10-K · Annual reportMar 2, 2026Annual reportSEC
8-K · Current reportMar 2, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeFeb 20, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
4 · Change in ownershipFeb 13, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeFeb 13, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 13, 2026Big-stake noticeSEC
144 · Notice of proposed saleFeb 12, 2026Other filingsSEC
4 · Change in ownershipJan 20, 2026Insider tradeSEC
144 · Notice of proposed saleJan 12, 2026Other filingsSEC
4 · Change in ownershipDec 19, 2025Insider tradeSEC
4 · Change in ownershipDec 16, 2025Insider tradeSEC
144 · Notice of proposed saleDec 12, 2025Other filingsSEC
4 · Change in ownershipDec 1, 2025Insider tradeSEC
3 · Initial statement of ownershipDec 1, 2025Insider tradeSEC
8-K · Current reportDec 1, 2025Management or board changeSEC
4 · Change in ownershipNov 25, 2025Insider tradeSEC
144 · Notice of proposed saleNov 21, 2025Other filingsSEC
4 · Change in ownershipNov 19, 2025Insider tradeSEC
144 · Notice of proposed saleNov 18, 2025Other filingsSEC
4 · Change in ownershipNov 17, 2025Insider tradeSEC
144 · Notice of proposed saleNov 17, 2025Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
144 · Notice of proposed saleNov 14, 2025Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
144 · Notice of proposed saleNov 13, 2025Other filingsSEC
10-Q · Quarterly reportNov 5, 2025Quarterly reportSEC
8-K · Current reportNov 5, 2025ResultsSEC
4 · Change in ownershipSep 17, 2025Insider tradeSEC
8-K · Current reportAug 21, 2025Current reportSEC
10-Q · Quarterly reportAug 14, 2025Quarterly reportSEC
8-K · Current reportAug 14, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
4 · Change in ownershipAug 7, 2025Insider tradeSEC
4 · Change in ownershipAug 7, 2025Insider tradeSEC
4 · Change in ownershipAug 7, 2025Insider tradeSEC
4 · Change in ownershipAug 7, 2025Insider tradeSEC
8-K · Current reportJun 30, 2025Current reportSEC
4 · Change in ownershipJun 20, 2025Insider tradeSEC
144 · Notice of proposed saleJun 18, 2025Other filingsSEC
144 · Notice of proposed saleJun 17, 2025Other filingsSEC
4 · Change in ownershipJun 16, 2025Insider tradeSEC
4 · Change in ownershipJun 16, 2025Insider tradeSEC
144 · Notice of proposed saleJun 16, 2025Other filingsSEC
144 · Notice of proposed saleJun 13, 2025Other filingsSEC
144 · Notice of proposed saleJun 12, 2025Other filingsSEC
4 · Change in ownershipJun 11, 2025Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedJun 6, 2025Big-stake noticeSEC
4 · Change in ownershipJun 6, 2025Insider tradeSEC
4 · Change in ownershipJun 2, 2025Insider tradeSEC
4 · Change in ownershipJun 2, 2025Insider tradeSEC
4 · Change in ownershipJun 2, 2025Insider tradeSEC
4 · Change in ownershipJun 2, 2025Insider tradeSEC
4 · Change in ownershipJun 2, 2025Insider tradeSEC
4 · Change in ownershipJun 2, 2025Insider tradeSEC
4 · Change in ownershipJun 2, 2025Insider tradeSEC
8-K · Current reportMay 29, 2025Meeting outcomeSEC
EFFECT · Notice that a registration is effectiveMay 19, 2025Other filingsSEC
SCHEDULE 13G · Big-stake noticeMay 15, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeMay 14, 2025Big-stake noticeSEC
CORRESP · Letter to the SECMay 14, 2025Other filingsSEC
SCHEDULE 13G · Big-stake noticeMay 14, 2025Big-stake noticeSEC
UPLOAD · Letter from the SECMay 12, 2025Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 12, 2025Big-stake noticeSEC
S-3 · Registration statementMay 8, 2025Offer documentSEC
10-Q · Quarterly reportMay 8, 2025Quarterly reportSEC
8-K · Current reportMay 8, 2025ResultsSEC
ARS · Annual report to shareholdersApr 18, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 18, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 18, 2025Meeting noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedMar 31, 2025Big-stake noticeSEC
10-K · Annual reportMar 27, 2025Annual reportSEC
8-K · Current reportMar 27, 2025ResultsSEC
4 · Change in ownershipMar 18, 2025Insider tradeSEC
4 · Change in ownershipMar 18, 2025Insider tradeSEC
SCHEDULE 13G · Big-stake noticeMar 6, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
4 · Change in ownershipFeb 7, 2025Insider tradeSEC
144 · Notice of proposed saleFeb 5, 2025Other filingsSEC
144 · Notice of proposed saleFeb 5, 2025Other filingsSEC
4 · Change in ownershipJan 31, 2025Insider tradeSEC
3 · Initial statement of ownershipJan 31, 2025Insider tradeSEC
8-K · Current reportJan 29, 2025Management or board changeSEC
4 · Change in ownershipJan 27, 2025Insider tradeSEC
144 · Notice of proposed saleJan 22, 2025Other filingsSEC
4 · Change in ownershipJan 21, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 21, 2025Big-stake noticeSEC
144 · Notice of proposed saleDec 9, 2024Other filingsSEC
SC 13D/A · Big-stake notice, amendedDec 6, 2024Big-stake noticeSEC
144 · Notice of proposed saleDec 5, 2024Other filingsSEC
144 · Notice of proposed saleDec 2, 2024Other filingsSEC
4 · Change in ownershipNov 26, 2024Insider tradeSEC
144 · Notice of proposed saleNov 20, 2024Other filingsSEC
SC 13D/A · Big-stake notice, amendedNov 19, 2024Big-stake noticeSEC
144 · Notice of proposed saleNov 14, 2024Other filingsSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13D/A · Big-stake notice, amendedNov 13, 2024Big-stake noticeSEC
4 · Change in ownershipNov 13, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedNov 12, 2024Big-stake noticeSEC
4 · Change in ownershipNov 8, 2024Insider tradeSEC
10-Q · Quarterly reportNov 7, 2024Quarterly reportSEC
8-K · Current reportNov 7, 2024ResultsSEC
4 · Change in ownershipNov 6, 2024Insider tradeSEC
4 · Change in ownershipNov 1, 2024Insider tradeSEC
4 · Change in ownershipNov 1, 2024Insider tradeSEC
144 · Notice of proposed saleOct 30, 2024Other filingsSEC
144 · Notice of proposed saleOct 30, 2024Other filingsSEC
144 · Notice of proposed saleOct 28, 2024Other filingsSEC
8-K · Current reportOct 28, 2024Current reportSEC
8-K · Current reportOct 25, 2024Management or board changeSEC
SC 13D/A · Big-stake notice, amendedOct 22, 2024Big-stake noticeSEC
4 · Change in ownershipOct 22, 2024Insider tradeSEC
3 · Initial statement of ownershipOct 22, 2024Insider tradeSEC
4 · Change in ownershipOct 22, 2024Insider tradeSEC
SC 13D/A · Big-stake notice, amendedOct 22, 2024Big-stake noticeSEC
4 · Change in ownershipOct 22, 2024Insider tradeSEC
8-K · Current reportOct 18, 2024FinancingSEC
4 · Change in ownershipOct 17, 2024Insider tradeSEC
144 · Notice of proposed saleOct 16, 2024Other filingsSEC
SC 13D/A · Big-stake notice, amendedOct 15, 2024Big-stake noticeSEC
SC 13D/A · Big-stake notice, amendedOct 15, 2024Big-stake noticeSEC
4 · Change in ownershipOct 2, 2024Insider tradeSEC
4 · Change in ownershipSep 25, 2024Insider tradeSEC
4 · Change in ownershipSep 20, 2024Insider tradeSEC
144 · Notice of proposed saleSep 20, 2024Other filingsSEC
144 · Notice of proposed saleSep 18, 2024Other filingsSEC
144 · Notice of proposed saleSep 18, 2024Other filingsSEC
144 · Notice of proposed saleSep 18, 2024Other filingsSEC
144 · Notice of proposed saleSep 18, 2024Other filingsSEC
144 · Notice of proposed saleSep 18, 2024Other filingsSEC
4 · Change in ownershipSep 17, 2024Insider tradeSEC
4 · Change in ownershipSep 17, 2024Insider tradeSEC
4 · Change in ownershipSep 10, 2024Insider tradeSEC
3 · Initial statement of ownershipSep 10, 2024Insider tradeSEC
4 · Change in ownershipAug 16, 2024Insider tradeSEC
4 · Change in ownershipAug 16, 2024Insider tradeSEC

This page holds 200 of 428 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Tyra Biosciences, Inc.’s releases · as of Nov 6, 2026

Common shares
69,082,747
Fully diluted
69,082,747

Fully diluted

LineSharesAs of
Common shares69,082,747Nov 6, 2026

Share count over time

CountShares
Nov 6, 202669,082,747

Open Cap table

Shareholders

Institutions

HolderSharesValueAs of
Ra Capital Management, L.P.12.2MUS$267MSep 30, 2026
Fidelity10.5MUS$230MSep 30, 2026
Janus Henderson5.26MUS$115MSep 30, 2026
Bvf Inc4.22MUS$92.2MSep 30, 2026
Alta Partners Management Company, L.P.3.82MUS$83.6MSep 30, 2026
Paradigm Biocapital Advisors LP3.51MUS$76.8MSep 30, 2026
TCG Crossover Management, LLC3.48MUS$76MSep 30, 2026
Nextech Invest Ltd.3.45MUS$75.4MSep 30, 2026
Siren, L.L.C.3.4MUS$74.3MSep 30, 2026
BlackRock3.36MUS$73.5MSep 30, 2026
Show 50 holders
HolderSharesValueAs of
T. Rowe Price2.58MUS$56.4MSep 30, 2026
Vanguard2.52MUS$55.2MSep 30, 2026
State Street2MUS$43.7MSep 30, 2026
Commodore Capital LP1.73MUS$37.7MSep 30, 2026
Geode Capital1.04MUS$22.7MSep 30, 2026
5AM Venture Management, LLC1.03MUS$22.5MSep 30, 2026
Hood River Capital Management LLC1.03MUS$22.5MSep 30, 2026
Trails Edge Capital Partners, LP1MUS$21.9MSep 30, 2026
Caligan Partners LP911KUS$19.9MSep 30, 2026
Affinity Asset Advisors, LLC850KUS$18.6MSep 30, 2026
Franklin Templeton841KUS$18.1MSep 30, 2026
Canaan Partners XI LLC750KUS$16.4MSep 30, 2026
Deerfield Management Company, L.P.732KUS$16MSep 30, 2026
Adage Capital Partners Gp, L.L.C.700KUS$15.3MSep 30, 2026
Two Sigma494KUS$10.8MSep 30, 2026
Jennison Associates LLC482KUS$10.5MSep 30, 2026
Integral Health Asset Management, LLC455KUS$9.95MSep 30, 2026
Goldman Sachs453KUS$9.9MSep 30, 2026
Soleus Capital Management, L.P.445KUS$9.73MSep 30, 2026
Schwab378KUS$8.27MSep 30, 2026
Bank of America376KUS$8.22MSep 30, 2026
Northern Trust346KUS$7.57MSep 30, 2026
Dimensional329KUS$7.19MSep 30, 2026
HighVista Strategies LLC227KUS$4.97MSep 30, 2026
Morgan Stanley207KUS$4.53MSep 30, 2026
Woodline Partners LP205KUS$4.49MSep 30, 2026
UBS196KUS$4.29MSep 30, 2026
BNP Paribas189KUS$4.14MSep 30, 2026
JPMorgan175KUS$3.87MSep 30, 2026
Raymond James Financial Inc171KUS$3.74MSep 30, 2026
Trexquant Investment LP168KUS$3.68MSep 30, 2026
Boothbay Fund Management, LLC146KUS$3.2MSep 30, 2026
Citadel137KUS$2.99MSep 30, 2026
Ensign Peak Advisors, Inc122KUS$2.68MSep 30, 2026
BNY104KUS$2.27MSep 30, 2026
Walleye Capital LLC95,576US$2.09MSep 30, 2026
AQR Capital Management LLC93,852US$2.05MSep 30, 2026
Jump Financial, LLC84,657US$1.85MSep 30, 2026
Oppenheimer & Co Inc82,072US$1.79MSep 30, 2026
Alps Advisors Inc79,051US$1.73MSep 30, 2026

This page holds 50 of 148 holders. Open Shareholders

Funds

HolderSharesValueAs of
Fidelity OTC Portfolio3.3MUS$105MJul 31, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF1.39MUS$44.5MJun 30, 2026
Vanguard Total Stock Market Index Fund1.14MUS$36.3MJun 30, 2026
iShares Russell 2000 ETF944KUS$30.2MJun 30, 2026
T. Rowe Price New Horizons Fund, Inc.793KUS$25.3MJun 30, 2026
Fidelity Advisor Equity Growth Fund679KUS$22.7MMay 31, 2026
VIP Growth Portfolio631KUS$20.1MJun 30, 2026
T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund559KUS$17.8MJun 30, 2026
Hood River Small-Cap Growth Fund492KUS$15.7MJun 30, 2026
Fidelity Small Cap Index Fund402KUS$12.8MJul 31, 2026
Show 50 holders
HolderSharesValueAs of
Fidelity Stock Selector Small Cap Fund390KUS$12.4MJul 31, 2026
Fidelity Small Cap Growth Fund375KUS$11.9MJul 31, 2026
Janus Henderson Triton Fund357KUS$11.4MJun 30, 2026
Fidelity Advisor Biotechnology Fund354KUS$11.3MJul 31, 2026
Fidelity Growth Discovery Fund342KUS$10.9MJun 30, 2026
Vanguard Extended Market Index Fund341KUS$10.9MJun 30, 2026
iShares Russell 2000 Growth ETF340KUS$10.8MJun 30, 2026
Select Biotechnology Portfolio337KUS$11.3MMay 31, 2026
iShares Biotechnology ETF315KUS$10MJun 30, 2026
T. Rowe Price Health Sciences Fund, Inc.304KUS$9.7MJun 30, 2026
Fidelity OTC K6 Portfolio290KUS$9.24MJul 31, 2026
Select Health Care Portfolio280KUS$9.35MMay 31, 2026
Fidelity Series Small Cap Opportunities Fund274KUS$8.75MJul 31, 2026
Fidelity Fund249KUS$7.94MJun 30, 2026
Janus Henderson Venture Fund212KUS$6.76MJun 30, 2026
Fidelity Small Cap Growth K6 Fund191KUS$6.1MJul 31, 2026
Vanguard Explorer Fund190KUS$6.07MJul 31, 2026
PGIM Jennison Health Sciences Fund183KUS$6.11MMay 29, 2026
Strategic Advisers Fidelity U.S. Total Stock Fund156KUS$5.22MMay 31, 2026
Fidelity Advisor Health Care Fund140KUS$4.46MJul 31, 2026
Vanguard Russell 2000 Index Fund133KUS$4.45MMay 31, 2026
Fidelity Extended Market Index Fund121KUS$4.04MMay 31, 2026
Schwab U.S. Small-Cap ETF114KUS$3.82MMay 31, 2026
VictoryShares US Small Mid Cap Value Momentum ETF105KUS$3.35MJun 30, 2026
North Square Dynamic Small Cap Fund97,364US$3.25MMay 31, 2026
Schwab Small-Cap Index Fund89,345US$2.85MJul 31, 2026
Fidelity Advisor Series Equity Growth Fund83,600US$2.79MMay 31, 2026
Vanguard U.S. Momentum Factor ETF81,594US$2.73MMay 31, 2026
Hood River New Opportunities Fund81,470US$2.6MJun 30, 2026
Fidelity Enhanced Small Cap Core ETF75,538US$2.41MJun 30, 2026
Fidelity SAI Small-Mid Cap Momentum Index Fund71,745US$2.29MJul 31, 2026
Master Small Cap Index Series68,768US$2.2MJun 30, 2026
T. Rowe Price Small-Mid Cap ETF68,709US$2.19MJun 30, 2026
Small Cap Equity Fund63,767US$2.04MJun 30, 2026
Franklin Biotechnology Discovery Fund62,752US$2MJul 31, 2026
T.Rowe Price Small Cap Growth Portfolio62,551US$2MJun 30, 2026
T. Rowe Price Integrated U.S. Small-Mid Cap Core Equity Fund60,843US$1.94MJun 30, 2026
JPMorgan U.S. Small Company Fund60,502US$1.93MJun 30, 2026
Dimensional U.S. Small Cap ETF55,674US$1.77MJul 31, 2026
ALPS Medical Breakthroughs ETF55,509US$1.85MMay 31, 2026

This page holds 50 of 195 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Verjee Rehan
Director
Buy972USD 20.58US$20,001Sep 9, 2026

Big stakes

StakeStakeSharesDateFiling
Ra Capital Management, L.P.19.90%14.1MSep 15, 2026Schedule 13D
FMR LLC14.40%7.75MMar 31, 2026Schedule 13G
Janus Henderson Group PLC7.20%3.89MMar 31, 2026Schedule 13G
BVF PARTNERS L P/IL6.10%4.22MSep 14, 2026Schedule 13G
Nextech VI Oncology SCSp6.00%3.55MJun 30, 2026Schedule 13G
Paradigm Biocapital Advisors LP5.80%3.47MSep 10, 2026Schedule 13G
TCG Crossover GP I, LLC5.70%2.9MFeb 27, 2025Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Rajeev M Shah
Other companies: Freenome, Inc. (Director · Since at least Jul 20, 2026); Parabilis Medicines, Inc. (Director · Since at least Jun 9, 2026); Hemab Therapeutics Holdings, Inc. (Director · Since at least Apr 30, 2026); SpyGlass Pharma, Inc. (Director · Since at least Feb 5, 2026); Evommune, Inc. (Director · Since at least Nov 5, 2025); Sionna Therapeutics, Inc. (Director · Since at least Feb 6, 2025); Septerna, Inc. (Director · Since at least Oct 24, 2024); Bicara Therapeutics Inc. (Director · Since at least Sep 12, 2024); Artiva Biotherapeutics, Inc. (Director · Since at least Jul 18, 2024); Cidara Therapeutics Inc (Director · Since at least Apr 24, 2024); LENZ Therapeutics, Inc. (Director · Since at least Mar 21, 2024); Mineralys Therapeutics, Inc. (Director · Since at least Feb 9, 2023); Acrivon Therapeutics, Inc. (Director · Since at least Nov 9, 2022); ARS Pharmaceuticals, Inc. (Director · Since at least Nov 8, 2022); PepGen Inc. (Director · Since at least May 5, 2022); Nkarta, Inc. (Director · Since at least Feb 14, 2022); Wave Life Sciences Ltd. (Director · Since at least Aug 16, 2021); Climb Bio, Inc. (Director · Since at least Aug 9, 2021); Acumen Pharmaceuticals, Inc. (Director · Since at least Jun 30, 2021); Janux Therapeutics, Inc. (Director · Since at least Jun 10, 2021); Vor Biopharma Inc. (Director · Since at least Feb 4, 2021); 89bio Inc (Director · Since at least Nov 8, 2019); Iteos Therapeutics Inc (Director · Jun 9, 2022 – Jun 9, 2022 · Past); Forma Therapeutics Holdings Inc (Director · Jun 8, 2022 – Jun 8, 2022 · Past); Icosavax Inc (Director · Jul 28, 2021 – Feb 19, 2024 · Past); Cytek Biosciences, Inc. (Director · Jul 22, 2021 – Mar 14, 2022 · Past); Jade Biosciences, Inc. (Director · Jun 29, 2021 – Jun 17, 2024 · Past); POINT Biopharma Global Inc (Director · Jun 23, 2021 – Jun 29, 2021 · Past); Werewolf Therapeutics, Inc. (Director · Apr 29, 2021 – May 12, 2025 · Past); Orchard Therapeutics PLC (Director · Feb 9, 2021 – Feb 9, 2021 · Past); Black Diamond Therapeutics, Inc. (Director · Jan 29, 2020 – Jul 5, 2023 · Past); Satsuma Pharmaceuticals Inc (Director · Sep 12, 2019 – Jun 6, 2023 · Past); Eidos Therapeutics Inc (Director · Jun 19, 2018 – May 27, 2020 · Past); Solid Biosciences Inc. (Director · Jan 25, 2018 – Jan 11, 2024 · Past); Kala Bio, Inc. (Director · Jul 19, 2017 – Jun 17, 2021 · Past); KalVista Pharmaceuticals, Inc. (Director · Nov 21, 2016 – Oct 12, 2017 · Past); Ra Pharmaceuticals Inc (Director · Oct 25, 2016 – Apr 2, 2020 · Past)
Director · Since at least Sep 14, 2021
Habib Joseph Dable
Other companies: SpyGlass Pharma, Inc. (Director · Since at least Feb 5, 2026); Relay Therapeutics, Inc. (Director · Since at least Nov 4, 2025); Day One Biopharmaceuticals Inc (Director · Since at least Jan 17, 2024); PepGen Inc. (Director · Since at least Sep 20, 2022); Blueprint Medicines Corp (Director · Since at least Jun 23, 2022); Jade Biosciences, Inc. (Director · Jul 10, 2023 – Jun 5, 2024 · Past); Albireo Pharma Inc (Director · Aug 8, 2022 – Mar 2, 2023 · Past); Acceleron Pharma Inc (CEO and President, Director · Jan 4, 2021 – Nov 19, 2021 · Past)
Director · Since at least Apr 16, 2026
Adele M. Gulfo
Other companies: NewAmsterdam Pharma Company N.V. (Director · Since at least Apr 15, 2025); Enpro Inc. (Director · Since at least Oct 30, 2018); Myovant Sciences Ltd (Director · Dec 27, 2019 – Mar 10, 2023 · Past); Bemis Company Inc (Director · Jun 23, 2015 – Jun 11, 2019 · Past)
Board Member · Since at least Jan 29, 2025
Susan Moran
Other companies: Crescent Biopharma, Inc. (Director · Since at least Jun 13, 2025); BioAtla, Inc. (Director · Since at least Dec 15, 2020); RayzeBio, Inc. (CHIEF MEDICAL OFFICER · Sep 14, 2023 – Feb 26, 2024 · Past)
Board member · Since at least May 7, 2024
Gilla Kaplan
Other companies: Avalo Therapeutics, Inc. (Director · Since at least Oct 8, 2020); Celgene Corporation (Director · Oct 30, 2006 – May 18, 2018 · Past)
Director · Since at least Sep 14, 2021
Robert More
Other companies: Vir Biotechnology, Inc. (Director · Since at least Oct 10, 2019); Glaukos Corporation (Director · Jun 24, 2015 – Jun 30, 2015 · Past)
Board Member · Since at least Sep 14, 2021
Alan Fuhrman
Other companies: SpringWorks Therapeutics Inc (Director · Since at least May 14, 2025)
Chief Financial Officer · Since at least Aug 7, 2025
Bhavesh Ashar
Other companies: SpringWorks Therapeutics Inc (Chief Commercial Officer · Since at least Mar 22, 2021)
Chief Operating Officer · Since at least Dec 1, 2025
Douglas J Warner
Other companies: eFFECTOR Therapeutics Inc (Chief Medical Officer · Aug 8, 2022 – Feb 19, 2024 · Past)
Chief Medical Officer · Since at least Sep 9, 2024
John Stephen Healy
Other companies: Contineum Therapeutics, Inc. (General Counsel and Corp Sec · Since at least May 30, 2024)
General Counsel and Secretary · Mar 1, 2022 – Mar 1, 2022 · Past
All 29 people
PersonSeat
Ali FawazGeneral Counsel and Secretary · Since at least May 16, 2022
Daniel BensenChief Discovery Officer · Since at least Feb 2, 2024
Doug WarnerChief Medical Officer · Since at least Nov 7, 2024
Heather FauldsChief Regulatory Officer · Since at least Dec 1, 2025
Isan ChenDirector · Sep 14, 2021 – May 31, 2023 · Past
Jake SimsonBoard Member · Since at least Nov 4, 2026
Jonathan DayEVP, Clinical Development · Since at least Aug 4, 2026
Liz PaganoChief Human Resources Officer · Since at least Nov 4, 2026
Melissa McCrackenBoard Member · Since at least Sep 14, 2021
Piyush PatelChief Development Officer · Since at least Sep 14, 2021
Rehan VerjeeBoard Member · Since at least Sep 14, 2021
Robert L. HudkinsChief Technology Officer · Since at least Nov 5, 2026
Ronald V. SwansonChief Scientific Officer · Since at least Sep 14, 2021
Sarah HonigSVP, Corporate Development & Strategy · Since at least Nov 4, 2026
Siddarth SubramonyDirector · Sep 14, 2021 – May 29, 2024 · Past
S. Michael RothenbergBoard Member · Since at least Nov 5, 2026
Stephen Michael RothenbergDirector · Since at least May 29, 2025
Todd HarrisChief Executive Officer · Since at least May 5, 2026
Yuliya RuebVice President, Finance (PAO) · Since at least Apr 1, 2026

Open People

Log in to ask 6ix AI your own questions about Tyra Biosciences, Inc.